StreetInsider.com News Articles

GenScript Reports 27.3% First-Half 2026 Revenue Growth as AI Drug Discovery Business Doubles

Tue, 18 Aug 2026 10:00:00 -0400

Adjusted net profit surges 203.3% as Gene-to-Protein generates two-thirds of GenScript Life Science Group revenue

PISCATAWAY, N.J., Aug. 18, 2026 /PRNewswire/ -- GenScript Biotech Corporation (HKEX: 1548) reported first-half revenue of approximately US$404.2 million on a comparable basis, up 27.3% year over year, while adjusted net profit rose 203.3% to approximately US$62.5 million. The results reflect strong growth across its core businesses, improved operating efficiency, and accelerating demand for AI-enabled drug discovery services.

GenScript Reports 27.3% First-Half 2026 Revenue Growth as AI Drug Discovery Business Doubles

Tue, 18 Aug 2026 10:00:00 -0400

Adjusted net profit surges 203.3% as Gene-to-Protein generates two-thirds of GenScript Life Science Group revenue

GenScript Reports 27.3% First-Half 2026 Revenue Growth as AI Drug Discovery Business Doubles

Tue, 18 Aug 2026 10:00:00 -0400

Adjusted net profit surges 203.3% as Gene-to-Protein generates two-thirds of GenScript Life Science Group revenue

GenScript Reports 27.3% First-Half 2026 Revenue Growth as AI Drug Discovery Business Doubles

Tue, 18 Aug 2026 10:00:00 -0400

Adjusted net profit surges 203.3% as Gene-to-Protein generates two-thirds of GenScript Life Science Group revenue

GenScript Reports 27.3% First-Half 2026 Revenue Growth as AI Drug Discovery Business Doubles

Tue, 18 Aug 2026 10:00:00 -0400

Adjusted net profit surges 203.3% as Gene-to-Protein generates two-thirds of GenScript Life Science Group revenue

GenScript Reports 27.3% First-Half 2026 Revenue Growth as AI Drug Discovery Business Doubles

Tue, 18 Aug 2026 10:00:00 -0400

Adjusted net profit surges 203.3% as Gene-to-Protein generates two-thirds of GenScript Life Science Group revenue

GenScript Reports 27.3% First-Half 2026 Revenue Growth as AI Drug Discovery Business Doubles

Tue, 18 Aug 2026 10:00:00 -0400

Adjusted net profit surges 203.3% as Gene-to-Protein generates two-thirds of GenScript Life Science Group revenue

GenScript Reports 27.3% First-Half 2026 Revenue Growth as AI Drug Discovery Business Doubles

Tue, 18 Aug 2026 10:00:00 -0400

Adjusted net profit surges 203.3% as Gene-to-Protein generates two-thirds of GenScript Life Science Group revenue

GenScript Reports 27.3% First-Half 2026 Revenue Growth as AI Drug Discovery Business Doubles

Tue, 18 Aug 2026 10:00:00 -0400

Adjusted net profit surges 203.3% as Gene-to-Protein generates two-thirds of GenScript Life Science Group revenue

GenScript Reports 27.3% First-Half 2026 Revenue Growth as AI Drug Discovery Business Doubles

Tue, 18 Aug 2026 10:00:00 -0400

Adjusted net profit surges 203.3% as Gene-to-Protein generates two-thirds of GenScript Life Science Group revenue

GenScript Reports 27.3% First-Half 2026 Revenue Growth as AI Drug Discovery Business Doubles

Tue, 18 Aug 2026 10:00:00 -0400

Adjusted net profit surges 203.3% as Gene-to-Protein generates two-thirds of GenScript Life Science Group revenue

GenScript Reports 27.3% First-Half 2026 Revenue Growth as AI Drug Discovery Business Doubles

Tue, 18 Aug 2026 10:00:00 -0400

Adjusted net profit surges 203.3% as Gene-to-Protein generates two-thirds of GenScript Life Science Group revenue

GenScript and Tamarind Bio Partner to Connect AI Molecular Design with Rapid Lab Validation

Wed, 05 Aug 2026 12:15:00 -0400

Collaboration combines Tamarind Bio's AI-powered molecular design platform with GenScript's wet-lab capabilities to help researchers move from digital concepts to experimental proof

PISCATAWAY, N.J. and SAN FRANCISCO, Aug. 5, 2026 /PRNewswire/ -- Artificial intelligence can now generate thousands of potential drug molecules in the time it once took to design one, dramatically expanding what scientists can imagine. Yet deciding which designs merit further investment still depends on experimental proof.

GenScript and Tamarind Bio Partner to Connect AI Molecular Design with Rapid Lab Validation

Wed, 05 Aug 2026 12:15:00 -0400

Collaboration combines Tamarind Bio's AI-powered molecular design platform with GenScript's wet-lab capabilities to help researchers move from digital concepts to experimental proof

GenScript and Tamarind Bio Partner to Connect AI Molecular Design with Rapid Lab Validation

Wed, 05 Aug 2026 12:15:00 -0400

Collaboration combines Tamarind Bio's AI-powered molecular design platform with GenScript's wet-lab capabilities to help researchers move from digital concepts to experimental proof

GenScript and Tamarind Bio Partner to Connect AI Molecular Design with Rapid Lab Validation

Wed, 05 Aug 2026 12:15:00 -0400

Collaboration combines Tamarind Bio's AI-powered molecular design platform with GenScript's wet-lab capabilities to help researchers move from digital concepts to experimental proof

GenScript and Tamarind Bio Partner to Connect AI Molecular Design with Rapid Lab Validation

Wed, 05 Aug 2026 12:15:00 -0400

Collaboration combines Tamarind Bio's AI-powered molecular design platform with GenScript's wet-lab capabilities to help researchers move from digital concepts to experimental proof

GenScript and Tamarind Bio Partner to Connect AI Molecular Design with Rapid Lab Validation

Wed, 05 Aug 2026 12:15:00 -0400

Collaboration combines Tamarind Bio's AI-powered molecular design platform with GenScript's wet-lab capabilities to help researchers move from digital concepts to experimental proof

GenScript and Tamarind Bio Partner to Connect AI Molecular Design with Rapid Lab Validation

Wed, 05 Aug 2026 12:15:00 -0400

Collaboration combines Tamarind Bio's AI-powered molecular design platform with GenScript's wet-lab capabilities to help researchers move from digital concepts to experimental proof

GenScript and Tamarind Bio Partner to Connect AI Molecular Design with Rapid Lab Validation

Wed, 05 Aug 2026 12:15:00 -0400

Collaboration combines Tamarind Bio's AI-powered molecular design platform with GenScript's wet-lab capabilities to help researchers move from digital concepts to experimental proof

ProBio and Curocell Achieve Key CAR-T Milestone with BLA Regulatory Approval and Commercial Readiness

Mon, 11 May 2026 07:51:00 -0400

Next-generation anti-CD19 CAR-T, Anbal-cel (CRC01), approval highlights Korean innovation

HOPEWELL, N.J., May. 11, 2026 /PRNewswire/ -- Given the accelerating global momentum in CAR-T and gene therapies, ProBio Inc. and Curocell have achieved a significant milestone with the BLA regulatory approval and commercial readiness of Anbalcabtagene autoleucel (Anbal-cel; code: CRC01). This next-generation CD19-targeted CAR-T cell therapy is developed for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This approval not only highlights Korea's growing innovation in advanced therapies but also marks a critical step towards bringing transformative treatment options to patients. To

ProBio and Curocell Achieve Key CAR-T Milestone with BLA Regulatory Approval and Commercial Readiness

Mon, 11 May 2026 07:51:00 -0400

Next-generation anti-CD19 CAR-T, Anbal-cel (CRC01), approval highlights Korean innovation

GenScript Leaders Named Entrepreneur Of The Year® 2026 New Jersey Finalists

Wed, 22 Apr 2026 15:26:00 -0400

PISCATAWAY, N.J., April 22, 2026 /PRNewswire/ -- GenScript Biotech Corporation today announced that CEO Sherry Shao and Co-Founder Dr. Frank Zhang have been selected as finalists for the Entrepreneur Of The Year® 2026 New Jersey Award by Ernst & Young LLP.

GenScript Leaders Named Entrepreneur Of The Year® 2026 New Jersey Finalists

Wed, 22 Apr 2026 15:26:00 -0400

GenScript Leaders Named Entrepreneur Of The Year® 2026 New Jersey Finalists

Wed, 22 Apr 2026 15:26:00 -0400